$SABS
SAB Biotherapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000143774923024224 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $1.267M $85.52K $6.351M
YoY Change -64.69% -98.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.570M $2.900M $4.309M
YoY Change -36.45% -32.7%
% of Gross Profit
Research & Development $4.020M $3.662M $8.481M
YoY Change -45.33% -56.82%
% of Gross Profit
Depreciation & Amortization $960.0K $870.0K $749.2K
YoY Change 8.45% 16.13%
% of Gross Profit
Operating Expenses $6.590M $6.562M $12.82M
YoY Change -42.18% -48.82% 4892.2%
Operating Profit -$5.323M -$6.477M -$6.543M
YoY Change -31.82% -1.01%
Interest Expense $69.70K $75.32K $1.604M
YoY Change -1.31% -95.3% 55198.62%
% of Operating Profit
Other Income/Expense, Net $220.6K -$404.3K $0.00
YoY Change -69.83% -100.0%
Pretax Income -$5.102M -$6.881M -$4.868M
YoY Change -27.89% 41.34% 121.07%
Income Tax $0.00 -$92.28K
% Of Pretax Income
Net Earnings -$5.102M -$6.881M -$4.776M
YoY Change -27.89% 44.07% 116.88%
Net Earnings / Revenue -402.59% -8046.13% -75.21%
Basic Earnings Per Share -$0.10 -$0.14 -$0.11
Diluted Earnings Per Share -$0.10 -$0.14 -$111.1K
COMMON SHARES
Basic Shares Outstanding 52.32M 50.40M 42.96M
Diluted Shares Outstanding 52.41M 5.042M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.400M $7.774M $16.62M
YoY Change -71.2% -53.21% 2095.62%
Cash & Equivalents $2.425M $7.774M $16.62M
Short-Term Investments
Other Short-Term Assets $700.0K $867.6K $1.521M
YoY Change -22.9% -42.97% 745.82%
Inventory
Prepaid Expenses $867.6K $1.775M
Receivables $0.00 $364.1K $9.613M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.128M $9.006M $27.75M
YoY Change -85.9% -67.55% 2862.68%
LONG-TERM ASSETS
Property, Plant & Equipment $20.62M $21.53M $30.87M
YoY Change -14.19% -30.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $434.0K $535.1K
YoY Change -20.22% -18.89%
Total Long-Term Assets $25.21M $26.44M $31.40M
YoY Change -16.87% -15.82% -72.96%
TOTAL ASSETS
Total Short-Term Assets $3.128M $9.006M $27.75M
Total Long-Term Assets $25.21M $26.44M $31.40M
Total Assets $28.34M $35.44M $59.15M
YoY Change -46.03% -40.09% -49.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.083M $1.404M $4.944M
YoY Change -80.25% -71.6%
Accrued Expenses $5.800M $6.453M $11.00M
YoY Change -48.98% -41.31% 7092.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $700.0K $238.9K $165.8K
YoY Change 321.94% 44.12%
Total Short-Term Liabilities $9.211M $11.01M $16.14M
YoY Change -46.14% -31.77% 10455.48%
LONG-TERM LIABILITIES
Long-Term Debt $3.500M $4.027M $3.695M
YoY Change -4.44% 9.0%
Other Long-Term Liabilities $400.0K $687.7K $2.202M
YoY Change -64.29% -68.76% -77.42%
Total Long-Term Liabilities $3.900M $4.715M $5.896M
YoY Change -18.46% -20.04% -39.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.211M $11.01M $16.14M
Total Long-Term Liabilities $3.900M $4.715M $5.896M
Total Liabilities $13.08M $15.73M $22.03M
YoY Change -40.23% -28.63% 122.46%
SHAREHOLDERS EQUITY
Retained Earnings -$67.20M -$62.10M -$32.92M
YoY Change 68.0% 88.64%
Common Stock $5.286K $5.286K $4.358K
YoY Change 21.29% 21.29%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.521M $5.521M $5.521M
YoY Change 0.0% 0.0%
Treasury Stock Shares $546.7K
Shareholders Equity $15.26M $19.72M $37.12M
YoY Change
Total Liabilities & Shareholders Equity $28.34M $35.44M $59.15M
YoY Change -46.03% -40.09% -49.48%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$5.102M -$6.881M -$4.776M
YoY Change -27.89% 44.07% 116.88%
Depreciation, Depletion And Amortization $960.0K $870.0K $749.2K
YoY Change 8.45% 16.13%
Cash From Operating Activities -$5.170M -$4.899M -$5.209M
YoY Change -36.75% -5.95% 5044.78%
INVESTING ACTIVITIES
Capital Expenditures $90.00K $22.68K -$612.8K
YoY Change -214.65% -103.7%
Acquisitions
YoY Change
Other Investing Activities $40.00K $0.00 $0.00
YoY Change
Cash From Investing Activities -$40.00K -$22.68K -$612.8K
YoY Change -49.04% -96.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -140.0K -363.8K 30.01K
YoY Change 335.19% -1312.23%
NET CHANGE
Cash From Operating Activities -5.170M -4.899M -5.209M
Cash From Investing Activities -40.00K -22.68K -612.8K
Cash From Financing Activities -140.0K -363.8K 30.01K
Net Change In Cash -5.350M -5.286M -5.792M
YoY Change -35.42% -8.74% 5620.41%
FREE CASH FLOW
Cash From Operating Activities -$5.170M -$4.899M -$5.209M
Capital Expenditures $90.00K $22.68K -$612.8K
Free Cash Flow -$5.260M -$4.922M -$4.596M
YoY Change -35.02% 7.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
SAB Biotherapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001833214
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52861314
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50940920
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52314656
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50394262
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
546658
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
546658
CY2021Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2022Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y11M15D
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P15Y5M1D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39871
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3899721
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 East 54th Street Nort
dei Entity Address City Or Town
EntityAddressCityOrTown
Sioux Falls
dei Entity Address State Or Province
EntityAddressStateOrProvince
SD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
57104
dei City Area Code
CityAreaCode
605
dei Local Phone Number
LocalPhoneNumber
679-6980
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52319156
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7774459 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15046894 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
364117 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5556577 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
867604 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1493982 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
9006180 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22097453 usd
CY2023Q2 sabs Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
434000 usd
CY2022Q4 sabs Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
467694 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
730583 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1192054 usd
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
3744185 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
3896873 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21527612 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23250853 usd
CY2023Q2 us-gaap Assets
Assets
35442560 usd
CY2022Q4 us-gaap Assets
Assets
50904927 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1403847 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3679116 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
111894 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
772665 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545964 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
490794 usd
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
127022 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
132788 usd
CY2023Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
2894781 usd
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
0 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5927527 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9917981 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11011035 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14993344 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91816 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
361225 usd
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3485754 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3629642 usd
CY2023Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
595860 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
320930 usd
CY2023Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
541644 usd
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
541644 usd
CY2023Q2 us-gaap Liabilities
Liabilities
15726109 usd
CY2022Q4 us-gaap Liabilities
Liabilities
19846785 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
5286 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5094 usd
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
5521246 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5521246 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87336872 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84444049 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62104461 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47869755 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
19716451 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31058142 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35442560 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50904927 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
85518 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6350525 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
666619 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18153601 usd
CY2023Q2 us-gaap Revenues
Revenues
85518 usd
CY2022Q2 us-gaap Revenues
Revenues
6350525 usd
us-gaap Revenues
Revenues
666619 usd
us-gaap Revenues
Revenues
18153601 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3662130 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8584427 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8197851 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21947692 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2900006 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4309042 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6347395 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9456191 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
6562136 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12893469 usd
us-gaap Operating Expenses
OperatingExpenses
14545246 usd
us-gaap Operating Expenses
OperatingExpenses
31403883 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6476618 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6542944 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13878627 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13250282 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
357516 usd
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1730080 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
274930 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9579652 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
75320 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
71237 usd
us-gaap Interest Expense
InterestExpense
167705 usd
us-gaap Interest Expense
InterestExpense
143259 usd
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
28568 usd
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
15824 usd
us-gaap Interest Income Other
InterestIncomeOther
86556 usd
us-gaap Interest Income Other
InterestIncomeOther
23757 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-404268 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1674667 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-356079 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9460150 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6880886 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4868277 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14234706 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3790132 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-92281 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6880886 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4775996 usd
us-gaap Net Income Loss
NetIncomeLoss
-14234706 usd
us-gaap Net Income Loss
NetIncomeLoss
-3790132 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50421262
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42999413
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50407412
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43048254
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38549913 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7830 usd
CY2022Q1 sabs Shares Issued Value Forward Purchase Agreement Partial Settlement
SharesIssuedValueForwardPurchaseAgreementPartialSettlement
817060 usd
CY2022Q1 sabs Repurchase Of Common Stock Pursuant To Forward Share Purchase Agreement Value
RepurchaseOfCommonStockPursuantToForwardSharePurchaseAgreementValue
0 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
897600 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
985863 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41258266 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
69141 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
569861 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4775996 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
37121272 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31058142 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1890 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
93530 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
602780 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7353820 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
24402522 usd
CY2023Q2 sabs Stock Issued During Period Value Settlement Of Accrued Liabilities
StockIssuedDuringPeriodValueSettlementOfAccruedLiabilities
1550000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
644815 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6880886 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
19716451 usd
us-gaap Net Income Loss
NetIncomeLoss
-14234706 usd
us-gaap Net Income Loss
NetIncomeLoss
-3790132 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1767226 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1385427 usd
sabs Rightofuse Assets Amortization
RightofuseAssetsAmortization
48209 usd
sabs Rightofuse Assets Amortization
RightofuseAssetsAmortization
73016 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1247595 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1467461 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
14278 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
274930 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9579652 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
143530 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5194842 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1601964 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-657689 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-324889 usd
sabs Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
-266755 usd
sabs Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
36056 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2275271 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
485058 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-2367 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2894781 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-100000 usd
sabs Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-2490453 usd
sabs Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-2597169 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6504873 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13985767 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
76390 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43984 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1970156 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43984 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1893766 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
660772 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1516833 usd
sabs Payments To Forward Share Purchase Agreement
PaymentsToForwardSharePurchaseAgreement
-0 usd
sabs Payments To Forward Share Purchase Agreement
PaymentsToForwardSharePurchaseAgreement
5521246 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
64696 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
87884 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1890 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76971 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-723578 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7048992 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7272435 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22928525 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15046894 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39545018 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7774459 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16616493 usd
us-gaap Interest Paid Net
InterestPaidNet
120022 usd
us-gaap Interest Paid Net
InterestPaidNet
143259 usd
sabs Issuance Of Common Stock Settlement Of Accrued Liabilities Value
IssuanceOfCommonStockSettlementOfAccruedLiabilitiesValue
1500000 usd
sabs Issuance Of Common Stock Settlement Of Accrued Liabilities Value
IssuanceOfCommonStockSettlementOfAccruedLiabilitiesValue
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">1</em>) Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> October 22, 2021 (</em>the “Closing Date”), we consummated the business combination contemplated by the agreement and plan of merger, dated as of <em style="font: inherit;"> June 21, 2021, </em>as amended on <em style="font: inherit;"> August 12, 2021, </em>made by and among Big Cypress Acquisition Corp., a Delaware corporation (“BCYP”), Big Cypress Merger Sub Inc., a Delaware corporation (“Merger Sub”), SAB Biotherapeutics, Inc., a Delaware corporation (“SAB” or “SAB Biotherapeutics” or the “Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative, agent and attorney-in-fact of the SAB Stockholders (the “Business Combination”). Upon closing of the Business Combination, Merger Sub merged with SAB Biotherapeutics, with SAB Biotherapeutics as the surviving company of the merger. Upon closing of the Business Combination, BCYP changed its name to “SAB Biotherapeutics, Inc.”</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SAB is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. SAB’s novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine™) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. However, SAB’s platform is the <em style="font: inherit;">first</em> to produce fully human antibodies in large animals.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Going Concern </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> June 30, 2023</em>, the Company has experienced net losses, negative cash flows from operations and had an accumulated deficit of $62.1 million. The Company anticipates to continue to generate losses for the foreseeable future and expects the losses to increase as the Company continues the development of, and seek regulatory approvals for, product candidates, and begin commercialization of products. As a result, the Company will require additional capital to fund operations in order to support long-term plans, in particular, following the JPEO Rapid Response Contract Termination (see Note <em style="font: inherit;">4,</em> <i>Revenue</i> for further information about the JPEO Rapid Response Contract Termination). These factors raise substantial doubt about the Company’s ability to continue as a going concern for the <em style="font: inherit;">one</em>-year period following the date that these financial statements were issued.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To continue as a going concern, the Company will need, among other things, to raise additional capital resources. The Company plans to seek additional funding through a combination of equity or debt financings, or other <em style="font: inherit;">third</em>-party financing, collaborative or other funding arrangements. Should the Company seek additional financing from outside sources, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to raise such financing on terms acceptable to the Company or at all. If the Company is unable to raise additional capital when required or on acceptable terms, the Company <em style="font: inherit;"> may </em>be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate assets, file for bankruptcy, reorganize, merge with another entity, or cease operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The unaudited consolidated financial statements as of <em style="font: inherit;"> June 30, 2023</em>, have been prepared on the basis that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that <em style="font: inherit;"> may </em>result from the possible inability for the Company to continue as a going concern.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62100000 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
0.4653 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Company has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Company’s common stock prior to becoming a public company, determination of the fair value of the Company’s warrants, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Company’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized <em style="font: inherit;"> may </em>differ from these estimates.</p>
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6880886 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of credit risk </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, <em style="font: inherit;"> may </em>exceed federally insured limits. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is <em style="font: inherit;">no</em> assurance that those institutions will be able to continue to do so. The Company has <em style="font: inherit;">not</em> experienced any credit losses associated with its balances in such accounts for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023 </em>and <em style="font: inherit;"> June 30, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company received 100% of its total revenue through grants from government organizations during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023 </em>and <em style="font: inherit;">2022</em>.</p>
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4775996 usd
us-gaap Net Income Loss
NetIncomeLoss
-14234706 usd
us-gaap Net Income Loss
NetIncomeLoss
-3790132 usd
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50421262
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42999413
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50407412
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43048254
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27099636
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19805489
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26826159
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20357470
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29614665 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29529375 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8087053 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6278522 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21527612 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23250853 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
870000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1770000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
750000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1390000 usd
us-gaap Acquisition Costs
AcquisitionCosts
5000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
621000 usd
sabs Finance Lease Payments
FinanceLeasePayments
231000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0642 pure
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0772 pure
CY2023Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
292655 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
200748 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
368320 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
401496 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
401496 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
401496 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
401496 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
4382998 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
660975 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
6189730 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23195 usd
CY2023Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
2576954 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
637780 usd
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
3612776 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545964 usd
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
127022 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91816 usd
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3485754 usd
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
23000 usd
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
32000 usd
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
71000 usd
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
71000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
48000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
73000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
140000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
143000 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
118000 usd
CY2023Q2 sabs Finance Lease Payments
FinanceLeasePayments
103000 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
309000 usd
CY2022Q2 sabs Finance Lease Payments
FinanceLeasePayments
110000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
236000 usd
sabs Finance Lease Payments
FinanceLeasePayments
206000 usd
CY2023Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
648909 usd
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
511849 usd
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
347676 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
357390 usd
CY2023Q2 sabs Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
0 usd
CY2022Q4 sabs Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
85767 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
290329 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
186833 usd
CY2023Q2 sabs Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
74658 usd
CY2022Q4 sabs Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
355479 usd
CY2023Q2 sabs Accrued Outside Lab Services
AccruedOutsideLabServices
467612 usd
CY2022Q4 sabs Accrued Outside Lab Services
AccruedOutsideLabServices
1106903 usd
CY2023Q2 sabs Accrued Bonus And Severance
AccruedBonusAndSeverance
35192 usd
CY2022Q4 sabs Accrued Bonus And Severance
AccruedBonusAndSeverance
950324 usd
CY2023Q2 sabs Accrued Contract Manufacturing
AccruedContractManufacturing
0 usd
CY2022Q4 sabs Accrued Contract Manufacturing
AccruedContractManufacturing
25129 usd
CY2023Q2 sabs Accrued Legal Liability
AccruedLegalLiability
803255 usd
CY2022Q4 sabs Accrued Legal Liability
AccruedLegalLiability
856505 usd
CY2023Q2 sabs Accrued Financing Fees Payable
AccruedFinancingFeesPayable
2910500 usd
CY2022Q4 sabs Accrued Financing Fees Payable
AccruedFinancingFeesPayable
4910500 usd
CY2023Q2 sabs Accrued Franchise Tax Payable
AccruedFranchiseTaxPayable
20000 usd
CY2022Q4 sabs Accrued Franchise Tax Payable
AccruedFranchiseTaxPayable
50000 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
55875 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8192 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
273521 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
513110 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5927527 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9917981 usd
CY2023Q2 sabs Insurance Policy Premiums Financed Value
InsurancePolicyPremiumsFinancedValue
1200000 usd
CY2023Q2 sabs Insurance Policy Premiums Financed Interest Rate
InsurancePolicyPremiumsFinancedInterestRate
0.0547 pure
CY2023Q2 sabs Insurance Financing Note Payable
InsuranceFinancingNotePayable
112000 usd
CY2022Q4 sabs Insurance Financing Note Payable
InsuranceFinancingNotePayable
773000 usd
CY2023Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12877631
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7095462
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.99
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M14D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109891 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2911750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
33847
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
32076
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.90
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9937789
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M2D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1660330 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4539909
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y2M23D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
637770 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4200000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M2D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.57
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
167000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
595000 usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
135000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
595000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
381000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
315000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1300000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.802 pure
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0350 pure
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
644815 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
569861 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1247595 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1467461 usd
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0020 pure
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2900000 usd
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1 pure
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03 pure
CY2023Q2 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
64000 usd
CY2022Q2 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
166000 usd
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
140000 usd
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
259000 usd

Files In Submission

Name View Source Status
sabs-20230630_cal.xml Edgar Link unprocessable
0001437749-23-024224-index-headers.html Edgar Link pending
0001437749-23-024224-index.html Edgar Link pending
0001437749-23-024224.txt Edgar Link pending
0001437749-23-024224-xbrl.zip Edgar Link pending
ex_526053.htm Edgar Link pending
ex_526054.htm Edgar Link pending
ex_526055.htm Edgar Link pending
ex_526056.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sabs-20230630.xsd Edgar Link pending
sabs20230630_10q.htm Edgar Link pending
Show.js Edgar Link pending
sabs-20230630_def.xml Edgar Link unprocessable
sabs-20230630_lab.xml Edgar Link unprocessable
sabs20230630_10q_htm.xml Edgar Link completed
sabs-20230630_pre.xml Edgar Link unprocessable